Jump to content
  • Sign Up
0
Scott Adams

ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic ... - MarketWatch (press release)

Rate this topic

Recommended Posts

ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic ...

MarketWatch (press release)

"ImmusanT's Nexvax2 and companion diagnostic address the rapidly growing number of patients diagnosed with celiac disease whose only option is a strict diet that eliminates gluten. At Vatera we seek to invest in therapies that fulfill unmet medical ...

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×